GO
| HSI1 | 25,238.22 | -72.99 | 144.32B |
| HSCEI1 | 8,395.01 | -55.09 | 40.78B |
| Back Zoom + Zoom - Block Traded | |
|
HUTCHMED Reaches Licensing Agreement With GSK for KRAS-EGFR Antibody-Drug Conjugate Cancer Therapy
2026-09-03 12:25:19 HUTCHMED (00013.HK) announced that it has entered into an exclusive development and license agreement with a subsidiary of GSK plc, granting the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830. Clinical development will initially focus on colorectal, pancreatic and lung cancer indications. The agreement includes a US$110 million upfront payment and potential development, regulatory and commercial milestone payments, for up to a total of US$1.295 billion, and royalties on net sales. This first-in-class drug candidate, an Antibody-Targeted Therapy Conjugate (ATTC), comprises a highly selective and potent Kirsten rat sarcoma (KRAS) small molecule inhibitor payload conjugated to an anti-epidermal growth factor receptor (EGFR) antibody. An ATTC enables tumor-selective activity of potent, cell-killing payloads by leveraging antibody-guided therapy. Under the terms of the agreement, HUTCHMED Limited will be responsible for the global phase I development program, which is expected to start in the second half of 2026 (clinicaltrials.gov identifier NCT07718581). The GSK subsidiary will be responsible for all subsequent clinical development and commercialization activities outside of Mainland China, Hong Kong, Macau and Taiwan. ~ AASTOCKS Financial News Website: www.aastocks.com | |